News Focus
News Focus
Followers 64
Posts 11870
Boards Moderated 0
Alias Born 07/16/2006

Re: jbog post# 17868

Wednesday, 11/01/2017 8:12:45 AM

Wednesday, November 01, 2017 8:12:45 AM

Post# of 20689
Momenta today announced that M834 did not meet its primary pharmacokinetic endpoints in a Phase 1 study to compare the pharmacokinetics, safety and immunogenicity of M834 to US- and EU-sourced ORENCIA in normal healthy volunteers. Momenta and Mylan continue to gather and analyze these data to inform the next steps for the program.


Not nice but we're all used to it by now. This is going to hurt.